Lower risk of heart attack with VKAs than with DOACs, aspirin

Prescription medications
Photo courtesy of the CDC
A large, retrospective study suggests patients with atrial fibrillation may have a lower risk of acute myocardial infarction (AMI) if they receive vitamin K antagonists (VKAs) rather than other anticoagulants. Investigators found that patients taking direct oral anticoagulants (DOACs, rivaroxaban or dabigatran) had more than twice... [Read Article]

Study supports use of rivaroxaban to prevent VTE recurrence

Rivaroxaban (Xarelto)
Results of the EINSTEIN CHOICE study suggest rivaroxaban is more effective than, and just as safe as, aspirin for long-term anticoagulation in patients with venous thromboembolism (VTE). In this phase 3 study, patients who had completed 6 to 12 months of anticoagulant therapy were randomized to receive rivaroxaban or aspirin.... [Read Article]

Major bleeding lower with dabigatran than warfarin

Dabigatran (Pradaxa)
Photo from Boehringer
Ingelheim Pharmaceuticals
Results from the RE-CIRCUIT trial suggest that uninterrupted dabigatran poses a lower risk of major bleeding than uninterrupted warfarin in patients with non-valvular atrial fibrillation (NVAF) who are undergoing catheter ablation. Patients who received dabigatran also had fewer serious and severe adverse events (AEs). ... [Read Article]

Computerized systems reduce risk of VTE, analysis suggests

Team performing surgery
Photo by Piotr Bodzek
The use of computerized clinical decision support systems can reduce the risk of venous thromboembolism (VTE) among surgical patients, according to new research. Results of a review and meta-analysis showed that use of these computerized systems was associated with a significant increase in the proportion... [Read Article]